BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23717622)

  • 1. Proper indication of BRAF(V600E) mutation testing in fine-needle aspirates of thyroid nodules.
    Koh J; Choi JR; Han KH; Kim EK; Yoon JH; Moon HJ; Kwak JY
    PLoS One; 2013; 8(5):e64505. PubMed ID: 23717622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of
    Chen X; Zhou Q; Wang F; Zhang F; Du H; Zhang Q; Wu W; Gong X
    AJNR Am J Neuroradiol; 2018 Dec; 39(12):2360-2365. PubMed ID: 30498021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomorphologic features in thyroid nodules read as "suspicious for malignancy" on cytology may predict thyroid cancers with the BRAF mutation.
    Kwon HJ; Kim EK; Kwak JY
    Pathol Res Pract; 2015 Sep; 211(9):671-6. PubMed ID: 26187369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additional BRAF mutation analysis may have additional diagnostic value in thyroid nodules with "suspicious for malignant" cytology alone even when the nodules do not show suspicious US features.
    Seo JY; Kim EK; Kwak JY
    Endocrine; 2014 Sep; 47(1):283-9. PubMed ID: 24452872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF
    Chen H; Song A; Wang Y; He Y; Tong J; Di J; Li C; Zhou Z; Cai X; Zhong D; Da J
    Cancer Med; 2022 Jan; 11(1):40-49. PubMed ID: 34851044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What to do with thyroid nodules showing benign cytology and BRAF(V600E) mutation? A study based on clinical and radiologic features using a highly sensitive analytic method.
    Kim SY; Kim EK; Kwak JY; Moon HJ; Yoon JH
    Surgery; 2015 Feb; 157(2):354-61. PubMed ID: 25616949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: a potential guide for selection of samples for molecular analysis.
    Nam SY; Han BK; Ko EY; Kang SS; Hahn SY; Hwang JY; Nam MY; Kim JW; Chung JH; Oh YL; Shin JH
    Thyroid; 2010 Mar; 20(3):273-9. PubMed ID: 20187782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic values of BRAF(V600E) mutation analysis and Bethesda system for reporting thyroid cytopathology in thyroid nodules with TIRADS 4 and 5].
    Han Y; Zhao BW; Li SY; Lyu JG; Shou JD; Xu HS; Lou HY; Xu LL; Gao L; Xu SX; Zhu J
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Sep; 52(9):686-691. PubMed ID: 28910894
    [No Abstract]   [Full Text] [Related]  

  • 9. Testing for BRAF (V600E) Mutation in Thyroid Nodules with Fine-Needle Aspiration (FNA) Read as Suspicious for Malignancy (Bethesda V, Thy4, TIR4): a Systematic Review and Meta-analysis.
    Trimboli P; Scappaticcio L; Treglia G; Guidobaldi L; Bongiovanni M; Giovanella L
    Endocr Pathol; 2020 Mar; 31(1):57-66. PubMed ID: 31811566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of BRAF(V600E) mutation analysis of thyroid nodules according to ultrasonographic features and the time of aspiration.
    Moon HJ; Kim EK; Chung WY; Choi JR; Yoon JH; Kwak JY
    Ann Surg Oncol; 2011 Mar; 18(3):792-9. PubMed ID: 20945104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF
    Zhao CK; Zheng JY; Sun LP; Xu RY; Wei Q; Xu HX
    Cancer Med; 2019 Sep; 8(12):5577-5589. PubMed ID: 31397092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of TIRADS, BSRTC and FNA-BRAF V600E mutation analysis in differentiating high-risk thyroid nodules.
    Zhang YZ; Xu T; Cui D; Li X; Yao Q; Gong HY; Liu XY; Chen HH; Jiang L; Ye XH; Zhang ZH; Shen MP; Duan Y; Yang T; Wu XH
    Sci Rep; 2015 Nov; 5():16927. PubMed ID: 26597052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical role of BRAF V600E mutation testing in thyroid nodules].
    Wan H; Zhang B; Wang Y; Xiao T; Guo H; Liu W; Yan D; Xu Z; Tang P
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Jun; 49(6):468-72. PubMed ID: 25241863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial clinical experience with BRAF(V600E) mutation analysis of core-needle biopsy specimens from thyroid nodules.
    Choi SH; Baek JH; Lee JH; Choi YJ; Ha EJ; Song DE; Kim JK; Chung KW; Kim TY; Kim WB; Shong YK
    Clin Endocrinol (Oxf); 2016 Apr; 84(4):607-13. PubMed ID: 26215382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is follow-up BRAF(V600E) mutation analysis helpful in the differential diagnosis of thyroid nodules with negative results on initial analysis?
    Yoon JH; Kim EK; Moon HJ; Kwak JY
    PLoS One; 2013; 8(3):e58592. PubMed ID: 23505540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of the BRAF mutation analysis in calcified thyroid nodules.
    Yoo EY; Shin JH; Ko EY; Han BK
    AJR Am J Roentgenol; 2012 Apr; 198(4):891-5. PubMed ID: 22451557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAFV600E mutation testing in fine needle aspirates of thyroid nodules: potential value of real-time PCR.
    Kwak JY; Han KH; Yoon JH; Kim EK; Moon HJ; Kim YL; Park SJ; Choi JR
    Ann Clin Lab Sci; 2012; 42(3):258-65. PubMed ID: 22964613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of BRAF V600E Mutation and Cytomorphological Features for the Optimization of Papillary Thyroid Cancer Diagnostics in Cytologically Indeterminate Thyroid Nodules.
    Beiša A; Kvietkauskas M; Beiša V; Stoškus M; Ostanevičiūtė E; Jasiūnas E; Griškevičius L; Šeinin D; Šileikytė A; Strupas K
    Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):247-254. PubMed ID: 29566402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study.
    Rossi M; Buratto M; Bruni S; Filieri C; Tagliati F; Trasforini G; Rossi R; Beccati MD; Degli Uberti EC; Zatelli MC
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2354-61. PubMed ID: 22535974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area.
    Lee ST; Kim SW; Ki CS; Jang JH; Shin JH; Oh YL; Kim JW; Chung JH
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2299-306. PubMed ID: 22500044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.